• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

    7/12/23 8:19:51 AM ET
    $ADIL
    $ASTI
    $BANL
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Semiconductors
    Technology
    Get the next $ADIL alert in real time by email

    Gainers

    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) shares gained 64.7% to $5.37 in pre-market trading after adding over 8% on Tuesday.
    • FLJ Group Limited (NASDAQ:FLJ) shares rose 27.1% to $0.3661 in pre-market trading after declining around 5% on Tuesday.
    • Enochian Biosciences Inc. (NASDAQ:ENOB) shares rose 26.4% to $0.6321 in pre-market trading. On July 7, 2023, Enochian Biosciences received a deficiency notice from the Nasdaq Stock Market informing the company that its common stock, par value $0.0001 per share, failed to comply with the $1 minimum bid price.
    • Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) gained 22.7% to $9.30 in pre-market trading. Eloxx Pharmaceuticals shares jumped 94% on Tuesday after Oppenheimer raised its price target from $50 to $55.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) gained 10.3% to $0.57 in pre-market trading.
    • Data Storage Corporation (NASDAQ:DTST) rose 9.8% to $2.79 in pre-market trading. Data Storage recently reported a large, subscription-based contract with a leading promotional products company.
    • CBL International Limited (NASDAQ:BANL) rose 9.1% to $5.44 in pre-market trading after jumping over 12% on Tuesday.
    • Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares climbed 8% to $0.1242 in pre-market trading. Ascent Solar Technologies recently reported bridge financing of up to 900 series 1B convertible preferred shares for $1,000 per share for aggregate gross proceeds of $900,000.
    • ImmuCell Corporation (NASDAQ:ICCC) shares gained 4.2% to $5.19 in pre-market trading. ImmuCell reported preliminary sales of $3.53 million for the second quarter, down from $3.86 million in the previous year.

    Losers

    • Silk Road Medical, Inc (NASDAQ:SILK) fell 22.1% to $25.43 in pre-market trading. Silk Road Medical is expected to report financial results for the second quarter 2023 on Aug. 1, 2023. JP Morgan downgraded Silk Road Medical from Overweight to Neutral and lowered the price target from $50 to $28.
    • ShiftPixy, Inc. (NASDAQ:PIXY) fell 20.9% to $1.89 in pre-market trading.
    • PainReform Ltd. (NASDAQ:PRFX) fell 19.2% to $13.33 in pre-market trading after jumping 307% on Tuesday.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 12.9% to $5.25 in pre-market trading after surging 42% on Tuesday.
    • Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares fell 11.4% to $0.3411 in pre-market trading. Adial Pharmaceuticals shares jumped 90% on Tuesday after the company provided business update following favorable comments from US, EU regulatory meetings.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) shares fell 11% to $1.38 in pre-market trading after rising over 20% on Tuesday.
    • CytoMed Therapeutics Limited (NASDAQ:GDTC) shares dropped 9.8% to $5.09 in pre-market trading after climbing 62% on Tuesday.
    • Cingulate Inc. (NASDAQ:CING) fell 9.4% to $0.77 in pre-market trading. Cingulate recently announced top-line results from its Phase 3 adult efficacy and safety trial of CTx-1301 for ADHD.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 7.3% to $0.1009 in pre-market after gaining around 7% on Tuesday.
    • Purple Biotech Ltd. (NASDAQ:PPBT) fell 6.2% to $1.29 in pre-market trading. Purple Biotech recently reported results of CM24 dose escalation in advanced pancreatic cancer patients.

     

    Now Read This: Investor Optimism Improves Ahead Of Inflation Data

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ASTI
    $BANL
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Silk Road Medical Inc.
    $SILK
    7/11/2024Buy → Sell
    Argus
    Silk Road Medical Inc.
    $SILK
    3/7/2024$24.00Hold → Buy
    Argus
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    Silk Road Medical Inc.
    $SILK
    1/19/2024$9.00 → $20.00Hold → Buy
    Stifel
    Silk Road Medical Inc.
    $SILK
    1/3/2024$20.00Buy
    Lake Street
    Cingulate Inc.
    $CING
    12/22/2023Buy → Hold
    Laidlaw
    More analyst ratings

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

    TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

    2/11/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan

    PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industry, today announced that it will effect a 1-for-60 reverse stock split of its common stock. The reverse stock split will become effective at 12:01 a.m. Eastern Time on Tuesday, February 10, 2026, and the Company's common stock will commence trading on the Nasdaq Capital Market on a post-split basis at the opening of the market on February 10, 2026, pending confirmation by the Depository Trust Company and the Nasdaq. The Company

    2/6/26 10:19:00 AM ET
    $HCTI
    EDP Services
    Technology

    Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

    Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00

    2/5/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    SEC Filings

    View All

    SEC Form 424B3 filed by Ascent Solar Technologies Inc.

    424B3 - Ascent Solar Technologies, Inc. (0001350102) (Filer)

    2/12/26 4:10:14 PM ET
    $ASTI
    Semiconductors
    Technology

    SEC Form EFFECT filed by Ascent Solar Technologies Inc.

    EFFECT - Ascent Solar Technologies, Inc. (0001350102) (Filer)

    2/12/26 12:15:15 AM ET
    $ASTI
    Semiconductors
    Technology

    SEC Form 6-K filed by CBL International Limited

    6-K - CBL International Ltd (0001914805) (Filer)

    2/11/26 4:15:22 PM ET
    $BANL
    Oil Refining/Marketing
    Energy

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Adial Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00

    11/14/24 7:21:37 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silk Road Medical downgraded by Argus

    Argus downgraded Silk Road Medical from Buy to Sell

    7/11/24 7:47:06 AM ET
    $SILK
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chairman and CEO Piluso Charles M. was granted 160,600 shares, increasing direct ownership by 180% to 250,032 units (SEC Form 4)

    4/A - Data Storage Corp (0001419951) (Issuer)

    2/12/26 5:02:30 PM ET
    $DTST
    EDP Services
    Technology

    Chairman and CEO Piluso Charles M. was granted 160,600 shares, increasing direct ownership by 180% to 250,032 units (SEC Form 4)

    4 - Data Storage Corp (0001419951) (Issuer)

    2/11/26 4:58:42 PM ET
    $DTST
    EDP Services
    Technology

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Data Storage Corporation Announces Strategic Advisory Appointments, Launches New Website, and Provides Business Update on Future Strategy

    MELVILLE, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Data Storage Corporation (NASDAQ:DTST) ("Data Storage" or the "Company"), today announced the appointment of a group of experienced strategic advisors to support the execution of its post-tender offer strategy and the launch of a newly redesigned corporate website. The Company also provided a business update as it advances its next phase of growth. The advisory team has been assembled to assist management execute its strategy centered on acquiring and supporting technology-enabled service businesses with high margins, recurring revenue, and attractive valuation profiles, while remaining selective in evaluating strategic investments that

    1/14/26 8:30:00 AM ET
    $DTST
    EDP Services
    Technology

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ASTI
    $BANL
    $BDRX
    Financials

    Live finance-specific insights

    View All

    ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

    PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects to continue providing this prompt, preliminary report on product sales until further notice. The Company will also include a geographic and product line sales breakdown going forward. Tot

    1/8/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

    PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and away from Re-Tain® on December 24, 2025. The Company will also discuss its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which will be announced after the market closes on Thursday, January 8, 2026. Conference Calls:

    1/7/26 8:10:57 AM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

    PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expanding its First Defense® manufacturing capabilities. In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Te

    12/24/25 1:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care